An evidence-based review on bexarotene (original) (raw)
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion
R. Knobler
British Journal of Dermatology, 2006
View PDFchevron_right
Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas
Kazuhiro Kawai
Journal of Dermatology, 2016
View PDFchevron_right
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR- receptor
Sunita Zafar
Blood, 2008
View PDFchevron_right
Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma
Waldemar Kulikowski
American Journal of Therapeutics, 2014
View PDFchevron_right
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action
Parul Hazarika
Clinical cancer research : an official journal of the American Association for Cancer Research, 2002
View PDFchevron_right
Oral Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma
Siu-fun Wong
The Annals of Pharmacotherapy, 2001
View PDFchevron_right
Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)
Kazuhiro Kawai
The Journal of Dermatology, 2019
View PDFchevron_right
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Cezary Swider
Clinical Cancer Research, 2008
View PDFchevron_right
Validated liquid chromatographic method for the determination of bexarotene in human plasma
Gregory Loewen
Journal of Chromatography B, 2002
View PDFchevron_right
Phase II Trial of Bexarotene Capsules in Patients With Advanced Non–Small-Cell Lung Cancer After Failure of Two or More Previous Therapies
Lee Schwartzberg
Journal of Clinical Oncology, 2006
View PDFchevron_right
Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study
Stephen Schuster
Clinical Lymphoma Myeloma and Leukemia, 2018
View PDFchevron_right
Photodegradation of Bexarotene and Its Implication for Cytotoxicity
Paweł Żmudzki
Pharmaceutics
View PDFchevron_right
Reverse Phase High Performance Liquid Chromatographic Method for Determination of Bexarotene in Capsule Dosage Form
Smita Nayak
INDIAN DRUGS, 2018
View PDFchevron_right
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma
CONSTANCE CROWLEY
Archives of dermatology, 2001
View PDFchevron_right
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial
CONSTANCE CROWLEY
Journal of the American Academy of Dermatology, 2003
View PDFchevron_right
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms
Jacqueline Junkins-hopkins
Journal of the American Academy of Dermatology, 2004
View PDFchevron_right
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
Julia Scarisbrick
British journal of cancer, 2013
View PDFchevron_right
Synthesis, Crystal Structure Analysis, and Pharmacological Characterization of Disila-bexarotene, a Disila-Analogue of the RXR-Selective Retinoid Agonist Bexarotene
Montana Mills
Organometallics, 2005
View PDFchevron_right
Expanding the Use of Retinoids in Acute Myeloid Leukemia: Spotlight on Bexarotene
Suzan McNamara
Clinical Cancer Research, 2008
View PDFchevron_right
Interactions of bexarotene (LGD1069, Targretin) with the coagulation system
Anne Hespel
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene
Drew Torigian
Cancer Biology & Therapy, 2008
View PDFchevron_right
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Charlotte Jacobs
Cancer Chemotherapy and Pharmacology, 2012
View PDFchevron_right
Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor-Selective Agonists: Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene)
Geoffrey Gray
ChemMedChem, 2012
View PDFchevron_right
Nanoformulation of dual bexarotene-tailed phospholipid conjugate with high drug loading
Kate Breslin
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017
View PDFchevron_right